Top Brand Name Drug Companies Bank Sky-High Profits While Evading Accountability
And that’s a wrap! Over three weeks of earnings calls have proven, yet again, that hiking prices is a profitable practice for an industry more concerned with pleasing its shareholders than helping patients.
This quarter, CSRxP tracked earnings reports from 12 of the world’s largest brand name drug companies – Johnson & Johnson, Eli Lilly, Roche, Novartis, Pfizer, Amgen, Merck, GlaxoSmithKline, Bristol-Myers Squibb, Abbvie and AstraZeneca. Every one of these Big Pharma giants reported gravy-train earnings for the fourth quarter of 2019 after hiking prices on American patients.
These results were not surprising considering Big Pharma’s record of price-gouging patients and fighting to maintain the status quo, despite the fact that 58 million Americans are unable to afford their prescription medications.
Read CSRxP’s “Big Pharma Earnings Watch” Blog on Johnson & Johnson HERE.
Read CSRxP’s “Big Pharma Earnings Watch” Blog on Eli Lilly, Roche, Novartis and Pfizer HERE.
Read CSRxP’s “Big Pharma Earnings Watch” Blog on Amgen HERE.
Read CSRxP’s “Big Pharma Earnings Watch” Blog on Merck, GlaxoSmithKline and Bristol-Myers Squibb HERE.
Read CSRxP’s “Big Pharma Earnings Watch” Blog on Abbvie HERE.
Read CSRxP’s “Big Pharma Earnings Watch” Blog on AstraZeneca HERE.
###